Medicine shortage has advanced to be a global issue. Countries, including the U.S., have tried to rectify the problem or lessen the impact. Modern strategies are being incorporated into the drug discovery process as the need to go beyond traditional methods was more than necessary. Pharma enterprises continue to explore possibilities in drug discovery. Optibrium assumes enormous significance in the scenario. Optibrium has been able to combine technology with drug discovery successfully. The high-end software solutions powered by Optibrium focus on small molecule design, data analysis, and optimization. The software solutions are deployed while arriving at decisions and enhancing efficiency in drug discovery.

“We continue to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. We also work closely with a broad range of customers and collaborators – including leading global pharma, biotech, agrochemical and flavoring companies, not-for-profit and academic groups,” says Company Director and CEO Matthew Segall.

Optibrium is based in the U.K. In addition, the company has a Cambridge, MA-based subsidiary. Here is a summary of what the enterprise has to offer:

THE OPTIBRIUM AUGMENTED CHEMISTRY-POWER OF ARTIFICIAL INTELLIGENCE

Optibrium successfully leverages the potential of artificial intelligence-powered services and software with its ‘Augmented Chemistry Software and Services.’ The Optibrium Augmented Chemistry enables the power of artificial intelligence to constantly learn from the entire range of critical data to support professional skills and experience. As a result, exciting or unique patterns are often highlighted, and it becomes easy to obtain intended goals to arrive at practical and insightful decisions that can impact the outcome of any research.

STARDROP – A COMPLETE PLATFORM WITH MULTIPLE FOCUS

Stardrop is a comprehensive platform for optimization, small molecule design, and data analysis. “With its comprehensive, integrated software suite, StarDrop™ delivers best-in-class in silico technologies within a highly visual and userfriendly interface. As a result, StarDrop™ enables a seamless flow from the latest data through predictive modeling to decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process,” informs Segall. With various available plug-in modules, predictive models for ADME characteristics, P450 metabolism, toxicity, automatic QSAR model generation, and de novo design to encourage the search for new optimization techniques, StarDrop’s main features can be expanded.

CERELLA

Cerella is a drug discovery software powered by A.I. CerellaTM employs a novel deep-learning approach to overcome data restrictions in drug discovery, which lowers costs and shortens drug discovery cycles.

The software has a critical eye for inaccurate or uncertain data. The high-quality compounds are precisely highlighted. Practical experiments are highlighted as well. As a result, Cerella boosts the decision-making process, identifies remote possibilities, and emphasizes false negatives and outliers. Cerella provides cloud-enabled deployment that can scale from small projects to large pharmaceutical databases.

OCURA

Ocura is a desktop application for analyzing chemistry data. Scientists are always searching for easier and faster ways to extract various chemical structures and sort the data quickly and effectively. Ocura will be the ideal solution for those. In addition, Ocura is a complimentary Windows® and Mac® desktop program. “Ocura enables you to load, scroll through, sort, and manage data in a new way, allowing you to view and manipulate chemical structures. Table View offers an innovative way to look at data in a traditional table that you can easily configure to suit your requirements. In addition, this visual interface enables you to smoothly scroll through the data in an informative way, offering a highly visual system to flick through your chemical structures,” concludes Segall.

I am honored to serve as the next CEO of Civica and continue our pivotal work of delivering quality generic medications that are available and affordable to everyone